[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 145
26. López-Köstner F, Fullerton DA, Kronberg U, Soto G, Zúñiga A, Argandoña J, Miranda V, Pinto E: [Screening colonoscopy among first degree relatives of patients with colorectal carcinoma]. Rev Med Chil; 2006 Aug;134(8):997-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the latter, a neoplasm was found in 13 (17%): One adenocarcinoma and 12 adenomas.
  • CONCLUSIONS: Screening colonoscopy is effective to detect adenoma and adenocarcinoma among first degree relatives of patients with colorectal carcinoma, however only 31% of all potential relatives agreed to undergo a colonoscopy.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / standards. Colorectal Neoplasms / diagnosis. Family Health. Mass Screening / psychology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adult. Age Factors. Aged. Attitude. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree. Prospective Studies. Risk Assessment


27. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


28. National Toxicology Program: Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study). Natl Toxicol Program Tech Rep Ser; 2008 Jan;(545):1-240
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In F(1)C females, there was a significant positive trend in the incidences of mammary gland adenoma or adenocarcinoma (combined) regardless of whether an unmodified or natural log-transformed dose scale was used in the analysis, and the incidence in the 500 ppm group was significantly greater than that in the control group.
  • In 5 and 100 ppm F(1)T140 females, the combined incidences of adenoma and adenocarcinoma were less than those in the control or 500 ppm groups, although these were not statistically significant differences.
  • When the natural log-transformed dose scale was used, a marginally significant positive trend occurred in the incidences of adenoma or adenocarcinoma (combined) in F(3)T21 females.
  • There were positive trends in the incidences of adenoma or carcinoma (combined) in the pars distalis of the pituitary gland of females in the F(1)C and F(1)T140 arms, and the incidence in the 500 ppm group was significantly greater than that in the controls in the F(1)C study arm.
  • In F(1)C males, a significant positive trend (unmodified dose scale only) occurred in the incidences of combined adenoma or carcinoma of the pancreatic islets.
  • There was some evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined) and pituitary gland neoplasms.
  • There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined).

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685716.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phytoestrogens; 0 / Xenobiotics; DH2M523P0H / Genistein
  •  go-up   go-down


29. Wada R: Proposal of a new hypothesis on the development of colorectal epithelial neoplasia: nonspecific inflammation--colorectal Paneth cell metaplasia--colorectal epithelial neoplasia. Digestion; 2009;79 Suppl 1:9-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal epithelial neoplasia (CR-EN), both adenoma and adenocarcinoma, may develop from the essential tubules of the colorectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Paneth Cells / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153484.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


30. Brouland JP, Gélébart P, Kovàcs T, Enouf J, Grossmann J, Papp B: The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol; 2005 Jul;167(1):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better characterize the role of SERCA3 in colon carcinogenesis, its expression has been investigated in colonic epithelium, benign lesions, adenomas, and adenocarcinomas.
  • We report that SERCA3 expression increased along the crypts as cells differentiated in normal colonic mucosa and in hyperplastic polyps, was moderately and heterogeneously expressed in colonic adenomas with expression levels inversely correlated with the degree of dysplasia, was barely detectable in well and moderately differentiated adenocarcinomas, and was absent in poorly differentiated tumors.
  • These data link SERCA3 expression to the state of differentiation of colonic epithelial cells, and relate SERCA3 expression, already decreased in adenomas, to enhanced adenomatous polyposis coli/beta-catenin/TCF4-dependent signaling and deficient Sp1-like factor-dependent transcription.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):82-92 [10384103.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Gene. 1999 Nov 29;240(2):261-7 [10580145.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14483-9 [1385815.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):G371-9 [1415549.001]
  • [Cites] Cell Calcium. 1993 Jul;14(7):531-8 [8402836.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2916-21 [7504695.001]
  • [Cites] Am J Med Sci. 1994 Mar;307(3):167-72 [8160706.001]
  • [Cites] J Mol Recognit. 1994 Sep;7(3):189-97 [7880543.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6 [8629105.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):299-306 [8825032.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10746-50 [9099725.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22199-206 [9268365.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):111-4 [9384695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1371-6 [10625687.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:195-9 [10667218.001]
  • [Cites] Science. 2000 Apr 14;288(5464):331-3 [10764645.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):203-7 [10913614.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):926-9 [10963297.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):795-804 [10996197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G806-14 [11005769.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):570-6 [11212251.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2413-22 [11259590.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):329-42 [11308031.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25742-52 [11337508.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):249-56 [11812948.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):122-8 [11943137.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16673-81 [11872750.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26310-20 [11986315.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):307-15 [12123752.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36471-8 [12119294.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):147-52 [12387883.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3245-53 [12401716.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45579-91 [12207029.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):269-78 [12543089.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):279-305 [12543090.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):405-11 [12543099.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):665-77 [12581631.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):107-17 [12633551.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3220-8 [12515718.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1861-2 [12692187.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):445-54 [12729578.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17785-91 [12624107.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):399-409 [12790808.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6023-31 [12955081.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47877-89 [12975374.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1041-3 [14647298.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43 [15047174.001]
  • [Cites] Curr Mol Med. 2004 May;4(3):313-22 [15101688.001]
  • [Cites] Annu Rev Biochem. 2004;73:437-65 [15189149.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1223-36 [15336970.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):687-98 [6476197.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1988 Jul;51(4):746-51 [3144112.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5447-59 [2548163.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13982-94 [9593748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60 [9707565.001]
  • [Cites] Biochim Biophys Acta. 1999 Jan 18;1444(1):85-91 [9931450.001]
  • [Cites] Nutr Rev. 1999 Apr;57(4):124-6 [10228349.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):779-85 [10353711.001]
  • (PMID = 15972967.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Trans-Activators; 0 / Transcription Factor 7-Like 2 Protein; 0 / Transcription Factors; 0 / beta Catenin; EC 3.6.3.8 / ATP2A3 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1603437
  •  go-up   go-down


76. Wang LP, Yang GZ, Zhou ZY, Li L, Gao BL, Chen J: [Clinicopathologic features and proliferative status of colorectal serrated lesions: a study of 104 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Feb;38(2):100-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features and proliferative status of colorectal hyperplastic polyp (HP), sessile serrated adenoma (SSA) and traditional serrated adenoma (TSA).
  • RESULTS: On the basis of morphologic examination, 60 cases were classified as HP, 20 cases as TSA, 11 cases as SSA, 7 cases as mixed HP/SSA/TSA, and 6 cases as mixed serrated polyp/adenoma and tubular adenoma.
  • The number and distribution of Ki-67 positive cells in SSA were similar to those in TSA but were significantly different from those in tubular adenoma and adenocarcinoma (chi2=34.601, P=0.000; chi2=63.077, P=0.000, respectively).
  • In general, the proliferative index is lower in serrated adenoma (TSA or SSA) than in tubular adenoma.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Intestinal Polyps / pathology. Ki-67 Antigen / metabolism
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Adult. Aged. Aged, 80 and over. Cell Proliferation. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Young Adult


77. Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ: Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol; 2009 Apr;40(4):443-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung lesions in CCSP(Cre-Neo)/LSL-K-ras(G12D) and CCSP(Cre)/LSL-K-ras(G12D) mice appeared at 4 and 1 month of age, respectively, and were classified as epithelial hyperplasia of the bronchioles, adenoma, and adenocarcinoma.

  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5054-8 [15289303.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Dec 1;164(11):2114-9 [11739144.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):949-57 [11698399.001]
  • [Cites] Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2 [11866137.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Eur Respir J. 2002 Sep;20(3):556-63 [12358328.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45547-57 [12237307.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Feb 15;167(4):587-92 [12433671.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Oct;31(4):382-94 [15191915.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):297-305 [15380520.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Med Clin North Am. 2004 Nov;88(6):1535-52, xi [15464112.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):433-9 [15489136.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):503-7 [3752756.001]
  • [Cites] Ann Intern Med. 1987 Apr;106(4):512-8 [3826952.001]
  • [Cites] Am J Physiol. 1991 Aug;261(2 Pt 1):L70-6 [1872417.001]
  • [Cites] J Natl Cancer Inst Monogr. 1992;(13):23-9 [1327034.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):432-8 [8319174.001]
  • [Cites] J Leukoc Biol. 1995 Mar;57(3):375-8 [7884307.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 1):1316-20 [7551388.001]
  • [Cites] J Histochem Cytochem. 1996 Aug;44(8):919-27 [8756763.001]
  • [Cites] Toxicol Lett. 1996 Nov;88(1-3):109-13 [8920724.001]
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):145-55 [9040936.001]
  • [Cites] Chest. 1997 Apr;111(4):885-90 [9106565.001]
  • [Cites] Eur Respir J. 1999 Nov;14(5):1015-22 [10596683.001]
  • [Cites] Semin Respir Infect. 2000 Mar;15(1):41-51 [10749549.001]
  • [Cites] Genesis. 2000 Nov-Dec;28(3-4):106-10 [11105051.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Am J Respir Crit Care Med. 2001 May;163(6):1304-9 [11371392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8774-9 [11438700.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 1997 Aug;97(2):229-32 [9344234.001]
  • [Cites] Chest. 1998 Apr;113(4 Suppl):235S-241S [9552012.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):885-90 [9615736.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1739-50 [9802985.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17723-8 [16317067.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2105-12 [16288213.001]
  • [Cites] Mol Cancer Res. 2006 Apr;4(4):221-33 [16603636.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 1;173(9):1016-22 [16456147.001]
  • [Cites] Eur Respir J. 2006 Sep;28(3):523-32 [16611654.001]
  • [Cites] J Pharmacol Exp Ther. 2007 May;321(2):734-42 [17322026.001]
  • [Cites] Swiss Med Wkly. 2007 Jun 2;137(21-22):304-11 [17629808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1119-27 [18281487.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jun;38(6):629-38 [18096867.001]
  • [Cites] PLoS One. 2008;3(5):e2220 [18493606.001]
  • [Cites] Genesis. 2008 Jun;46(6):300-7 [18543320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1193-9 [11700268.001]
  • (PMID = 18927348.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01 CA105352
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Bacterial Proteins; 0 / Chemokines; 0 / NF-kappa B; 0 / Porins; 0 / Scgb1a1 protein, mouse; 0 / ompP2 protein, Haemophilus influenzae; 9060-09-7 / Uteroglobin; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2660561
  •  go-up   go-down


78. Hong R, Lim SC: Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncol Rep; 2008 Apr;19(4):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological significance of connexin 26 expression in colorectal adenocarcinoma.
  • This study was conducted to determine the level of expression and cellular localization of connexin 26 (Cx26) and the expression of p53 in colorectal adenocarcinoma as well as their relationship to clinicopathological features.
  • Immunohistochemical staining was performed in 130 colorectal adenocarcinoma cases.
  • There was a statistical significant difference in the Cx26 expression level among normal epithelium (NE), adenomas and adenocarcinomas (p<0.001).
  • Of the 130 adenocarcinomas, 48.5% were positive for Cx26.
  • All of the adenoma and NE samples were positive for Cx26 expression; however, the level of expression of Cx26 in adenomas was smaller than the level of expression for NE.
  • Cytoplasmic staining for Cx26 was observed in the adenocarcinomas (23.8%), but was not observed in the adenoma and NE samples.
  • Expression of p53 was positive for 50% of the adenocarcinomas, and the level of p53 was increased in a reverse proportion to the level of Cx26 intercellular staining.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Connexins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexins; 127120-53-0 / connexin 26
  •  go-up   go-down


79. Xiao H, Hao X, Simi B, Ju J, Jiang H, Reddy BS, Yang CS: Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis; 2008 Jan;29(1):113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoid X receptor (RXR)alpha expression was reduced in high-grade dysplastic ACF, adenoma and adenocarcinoma during AOM-induced colon carcinogenesis, and the PPE treatment partially prevented the loss of RXRalpha expression in high-grade dysplastic ACF.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893236.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES005022
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


80. Ishiguro K, Yoshida T, Yagishita H, Numata Y, Okayasu T: Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas. Gut; 2006 May;55(5):695-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas.
  • BACKGROUND: Previously, we indicated that stromal genetic instability might contribute to tumorigenesis of both sporadic and ulcerative colitis associated colorectal adenocarcinomas.
  • Considering the established adenoma-adenocarcinoma sequence, in this study we analysed genetic instability in colorectal adenoma cells and surrounding stroma.
  • METHODS: In 164 colorectal tumours (34 hyperplastic polyps, 38 tubular adenomas with low grade dysplasia (TA-L), 51 tubular adenomas with high grade dysplasia (TA-H), and 41 invasive carcinomas), epithelial and stromal genetic instability with National Cancer Institute standard microsatellite markers and chromosome 17 (Chr17) markers, were analysed by a combination of laser capture microdissection and GeneScan approaches.
  • RESULTS: While frequencies of both loss of heterozygosity (LOH) and microsatellite instability (MSI) were extremely low in hyperplastic polyps, LOH in tubular adenomas was detected in both epithelial (TA-L 13.2%, TA-H 27.5%) and stromal (5.3% and 5.9%, respectively) elements, along with MSI (5.3% and 13.7%, and 5.3 and 5.9%, respectively).
  • On the other hand, frequencies of stromal LOH or MSI were almost constant (5.3% approximately 17.1%, 5.3% approximately 17.1%, respectively) in adenomas and invasive carcinomas.
  • Thus microenvironmental changes due to genetic alteration in Chr17 markers in stromal cells may play an important role in colon adenoma and adenocarcinoma development.
  • [MeSH-major] Adenoma / genetics. Biomarkers, Tumor / analysis. Chromosomes, Human, Pair 17. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Genomic Instability
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Chi-Square Distribution. Disease Progression. Epithelial Cells / metabolism. Female. Gene Frequency. Genes, p53. Genetic Markers. Humans. Immunohistochemistry / methods. Intestinal Mucosa / metabolism. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1994 Jun;7(2 Spec No):246-339 [7545953.001]
  • [Cites] Genomics. 1993 Sep;17(3):618-23 [8244378.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):40-5 [8978341.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):913-21 [9492020.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2562-6 [10811140.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1617-28 [11092522.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2236-8 [11956075.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2447-54 [11980631.001]
  • [Cites] J Pathol. 2003 Feb;199(2):166-75 [12533829.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):723-30 [12760292.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):707-12 [12915883.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6158-61 [14559796.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:845-9 [4851945.001]
  • [Cites] Gastroenterology. 1974 Oct;67(4):636-45 [4414719.001]
  • [Cites] N Engl J Med. 1987 Jun 25;316(26):1654-8 [3295551.001]
  • [Cites] Dig Dis Sci. 1988 Jun;33(6):673-8 [3371139.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):75-9 [2296606.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • (PMID = 16354798.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC1856111
  •  go-up   go-down


81. Hasumura M, Imai T, Takizawa T, Ueda M, Onose J, Hirose M: Promotion of thyroid carcinogenesis by para-aminobenzoic acid in rats initiated with N-bis(2-hydroxypropyl)nitrosamine. Toxicol Sci; 2005 Jul;86(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The final incidence of thyroid follicular cell adenomas and adenocarcinomas was significantly (p < 0.05 or 0.01) increased in groups 3 and 4 as compared to group 1.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. 4-AMINOBENZOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843508.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 0 / Thyroid Hormones; 53609-64-6 / diisopropanolnitrosamine; TL2TJE8QTX / 4-Aminobenzoic Acid
  •  go-up   go-down


82. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T: Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):338-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-two IPMNs, which consisted of 29 adenomas, 10 borderline tumors, 11 adenocarcinomas in situ, and invasive adenocarcinomas were reviewed from 1990 to 2003.
  • There was no recurrent disease in patients with adenoma and adenocarcinoma in situ, whereas recurrences occurred in 6 of 12 patients with invasive IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):163-71 [9196015.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):967-71 [11490850.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):900-5 [9041151.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):1-10 [7846994.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):962-6 [11490849.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):35-41 [11148557.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1041-7 [10931048.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):826-33 [8039110.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):117-21 [12622422.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):277-83 [12579258.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 17458608.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Lee DS, Kang SB, Baek JT, Nam SW, Lee KM, Ahn BM, Lee EH, Han SW, Chung IS: [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2005 Jun;45(6):394-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of bcl-2, bcl-xL, bax, p53 proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical expression of bcl-2, bcl-xL, bax, and p53 proteins according to the pathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in the gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal bcl-2, bcl-xL, bax, p53 antibodies were performed on paraffin embedded specimens from forty-one gastric adenomas and 100 gastric adenocarcinomas.
  • RESULTS: The expression rate of bcl-2 was higher in adenomas (34.2%), especially in high grade dysplasia (52.4%), than adenocarcinomas (2.0%).
  • The expression rate of bcl-xL was higher in adenocarcinomas (55.0%) than adenomas (22%).
  • The expression rate of the bax was higher in adenocarcinomas (58.0%) than adenomas (14.6%).
  • In the adenocarcinoma, the bax expression was significantly related with the depth of invasion, lymph node metastasis, and TNM stage.
  • The expression rate of p53 was higher in adenocarcinomas (64.0%) than adenomas (14.6%).
  • CONCLUSIONS: Bcl-2 protein would be related with the development of gastric adenoma, especially with high grade dysplasia.
  • Bcl-xL and p53 proteins would be involved in the development of relatively early stage of gastric adenocarcinoma but not in tumor progression.
  • Bax protein would be involved in the development of gastric adenocarcinoma and related with depth of invasion, lymph node metastasis, and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973073.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


8
Advertisement
4. Vinci A, Bacci B, Benazzi C, Caldin M, Sarli G: Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits. J Comp Pathol; 2010 May;142(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial adenocarcinoma is the most common uterine tumour of domestic rabbits.
  • The present immunohistochemical study examined the expression of cytokeratin 19 (CK19), the progesterone receptor (PR), the proliferation-associated antigen Ki-67 and telomerase in normal rabbit uterine tissue and examples of endometrial hyperplasia, adenoma and adenocarcinoma.
  • Tubulopapillary adenomas and adenocarcinomas were the most common histological subtypes in this series.
  • Cytoplasmic expression of CK19 was recorded in two of three samples of normal endometrium and in one of three samples of endometrial hyperplasia, in all adenomas and five of six adenocarcinomas.
  • PR was expressed within the nucleus of normal endometrial cells and in one of three samples of endometrial hyperplasia, each of four adenomas and in four of six adenocarcinomas.
  • Nuclear labelling of telomerase activity was found in one of three normal uteri, all samples of endometrial hyperplasia, two of four adenomas, but none of the adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Ki-67 Antigen / metabolism. Mitotic Index. Progesterone / metabolism. Prognosis. Rabbits. Telomerase / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096851.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


85. Fukuyama M, Rokutan K, Sano T, Miyake H, Shimada M, Tashiro S: Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon. Cancer Lett; 2005 Apr 18;221(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of a novel superoxide-producing enzyme, NADPH oxidase 1, in adenoma and well differentiated adenocarcinoma of the human colon.
  • Adenomas and well differentiated adenocarcinomas up-regulated Nox1 expression.
  • Nuclear factor (NF)-kappaB was predominantly activated in adenoma and adenocarcinoma cells expressing abundant Nox1, suggesting that Nox1 may stimulate NF-kappaB-dependent antiapoptotic pathways in colon tumors.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenoma / enzymology. Colonic Neoplasms / enzymology. NADPH Oxidase / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797632.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / NF-kappa B; EC 1.6.3.- / NOX1 protein, human; EC 1.6.3.1 / NADPH Oxidase
  •  go-up   go-down


86. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ: Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med; 2008 Sep 18;359(12):1207-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of CT colonography for detection of large adenomas and cancers.
  • The primary end point was detection by CT colonography of histologically confirmed large adenomas and adenocarcinomas (10 mm in diameter or larger) that had been detected by colonoscopy; detection of smaller colorectal lesions (6 to 9 mm in diameter) was also evaluated.
  • For large adenomas and cancers, the mean (+/-SE) per-patient estimates of the sensitivity, specificity, positive and negative predictive values, and area under the receiver-operating-characteristic curve for CT colonography were 0.90+/-0.03, 0.86+/-0.02, 0.23+/-0.02, 0.99+/-<0.01, and 0.89+/-0.02, respectively.
  • The per-polyp sensitivity for large adenomas or cancers was 0.84+/-0.04.
  • The per-patient sensitivity for detecting adenomas that were 6 mm or more in diameter was 0.78.
  • CONCLUSIONS: In this study of asymptomatic adults, CT colonographic screening identified 90% of subjects with adenomas or cancers measuring 10 mm or more in diameter.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Massachusetts Medical Society
  • [Cites] Radiology. 2000 May;215(2):353-7 [10796907.001]
  • [Cites] Radiology. 2005 Aug;236(2):519-26 [16040909.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):911-6 [12671887.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):311-9 [12891530.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Radiology. 2006 May;239(2):464-71 [16569789.001]
  • [Cites] Radiology. 2006 May;239(2):313-6 [16641348.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Br J Radiol. 2005 Jan;78(925):22-9 [15673525.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] J Periodontal Res. 1997 May;32(4):351-4 [9210088.001]
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):517-21 [8623619.001]
  • [Cites] J Clin Gastroenterol. 2004 Oct;38(9):767-71 [15365402.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):631-8 [14975961.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):314-21 [15067626.001]
  • [CommentIn] Ann Intern Med. 2009 Feb 17;150(4):JC2-13 [19238611.001]
  • [CommentIn] Gastroenterology. 2009 Apr;136(4):1451-3 [19233331.001]
  • [CommentIn] N Engl J Med. 2008 Sep 18;359(12):1285-7 [18799563.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842-3; author reply 2843-4 [19115494.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2843; author reply 2843-4 [19115493.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842; author reply 2843-4 [19109581.001]
  • [ErratumIn] N Engl J Med. 2008 Dec 25;359(26):2853
  • (PMID = 18799557.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00084929
  • [Grant] United States / NCI NIH HHS / CA / CA080098-10; United States / NCI NIH HHS / CA / U01 CA080098; United States / NCI NIH HHS / CA / U01 CA080098-10
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS73206; NLM/ PMC2654614
  •  go-up   go-down


87. Park MJ, Kim DH, Lim SH, Yim JY, Kim YS, Cho KR, Kim CH, Jung HC, Song IS, Kim SS, Yoon DH, Shin CS, Cho SH, Oh BH, Lee DH: Features of Gastric Neoplasm Detected during the Screening Examination. Gut Liver; 2007 Jun;1(1):33-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 25, 432 subjects, 122 cases of gastric neoplasms were detected including 61 adenocarcinoma (45 early gastric cancers), 53 adenoma, 7 mucosa-associated lymphoid tissue lymphoma, and one metastatic cancer.
  • There was no significant statistical difference in basal characteristics of the subjects between gastric adenocarcinoma and adenoma.
  • Metabolic syndrome was more prevalent in adenoma than in the control (p<0.05).
  • In addition, metabolic syndrome might be related with gastric adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1090-6 [9672336.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):419-24 [15998815.001]
  • [Cites] Ann Epidemiol. 1997 Oct;7(7):446-51 [9349911.001]
  • [Cites] Am J Gastroenterol. 1996 May;91(5):839-43 [8633568.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Am J Surg. 1989 Jul;158(1):14-6 [2742043.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):69-74 [14985987.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jan;34(1):1-7 [15020656.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Annu Rev Public Health. 2003;24:413-33 [12428034.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):204-8 [12590229.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1276-85 [12360042.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):446-9 [11920598.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):811-8 [11857360.001]
  • [Cites] Gut. 2002 Mar;50(3):378-81 [11839718.001]
  • [Cites] Surgery. 2000 Jul;128(1):41-7 [10876184.001]
  • [Cites] J Gastroenterol. 1999;34 Suppl 11:91-6 [10616774.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Aug;18(8):821-9 [16825897.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):709-16 [16765306.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii103-8 [16760271.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):35-7 [9533759.001]
  • (PMID = 20485656.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871660
  • [Keywords] NOTNLM ; Adenoma / Gastric cancer / Helicobacter pylori / Risk factor / Screening / Stomach
  •  go-up   go-down


88. Scherübl H, Klöppel G: [Rectal carcinoids on the rise - update]. Z Gastroenterol; 2009 Apr;47(4):365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to the early detection of colorectal adenoma and adenocarcinoma, screening colonoscopy also makes possible the early detection and early therapy for neuroendocrine rectal tumours/carcinomas.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358064.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


89. Habermann N, Schön A, Lund EK, Glei M: Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. Apoptosis; 2010 May;15(5):621-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo.
  • LT97 human colon adenoma and HT29 human colon adenocarcinoma cells were used to investigate modulation of apoptosis by EPA, DHA or linoleic acid (LA) using a set of endpoints, namely phosphatidylserine staining with Annexin-V (flow cytometry), Bcl-2 expression (Real-time RT-PCR), and Bid, caspase 3, 8 and 9 expression as well as PARP cleavage (Western Blot).
  • Taken together, our results show that adenoma cells are highly susceptible to n-3 PUFA-induced apoptosis.
  • [MeSH-major] Adenocarcinoma. Apoptosis / drug effects. Biomarkers / metabolism. Colorectal Neoplasms. Dietary Fats. Fatty Acids, Omega-3. Fishes

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20107900.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BH3 Interacting Domain Death Agonist Protein; 0 / Biomarkers; 0 / Caspase Inhibitors; 0 / Dietary Fats; 0 / Fatty Acids, Omega-3; 0 / Fish Oils; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases
  •  go-up   go-down


90. Scherübl H: Rectal carcinoids are on the rise: early detection by screening endoscopy. Endoscopy; 2009 Feb;41(2):162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, endoscopic screening of the colorectum is effective in the early diagnosis not only of colorectal adenomas and adenocarcinomas but also of carcinoids.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19214898.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down


91. Aubry K, Sauvage JP, Puyraud S: [Amphicrine adenoma of the middle ear: three cases reports and a review of the literature]. Rev Laryngol Otol Rhinol (Bord); 2006;127(3):145-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Amphicrine adenoma of the middle ear: three cases reports and a review of the literature].
  • Amphicrine adenoma is an extremely rare tumor of the middle ear.
  • Amphicrine adenoma is diagnosed by an immuno-histological examination of pathological specimens.
  • Differential diagnosis can be difficult and one individual was initially treated as an adenocarcinoma by radiotherapy.
  • CONCLUSION: Historically, differential diagnosis between amphicrine adenoma and adenocarcinoma of the middle ear has been very difficult.
  • Carcinoid tumour is considered to be a more agressive form of amphicrine adenoma.
  • [MeSH-major] Adenoma / pathology. Ear Neoplasms / pathology. Ear, Middle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007186.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 20
  •  go-up   go-down


92. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, Fang JY: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia; 2008 Mar;10(3):287-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, immunohistochemical staining reveals that nuclear staining of phospho-STAT3 mostly presents in adenomas and adenocarcinomas, and a positive correlation is found between phospho-JAK2 immunoreactivity and the differentiation of colorectal adenocarcinomas.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):257-70 [15713897.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):833-8 [16049285.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6406-17 [16007195.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1184-91 [16489072.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1445-51 [16685378.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2668-70 [16963263.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):224-33 [16819511.001]
  • [Cites] J Clin Pathol. 2007 Feb;60(2):173-9 [17264243.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1123-32 [17317820.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1577-85 [16953222.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2497-507 [17363567.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2517-25 [17363569.001]
  • [Cites] Leukemia. 2007 Apr;21(4):780-7 [17375124.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):12249-59 [17307743.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4940-8 [17510424.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3654-60 [17530019.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5389-96 [17545620.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5112-21 [17332240.001]
  • [Cites] Gut. 2007 Sep;56(9):1257-65 [17449633.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Science. 2000 Jan 7;287(5450):142-4 [10615050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5405-10 [10792035.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):10-24 [10862190.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1543-8 [11171987.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):327-34 [11310826.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17397-405 [11859072.001]
  • [Cites] Eur J Clin Invest. 2002 Jun;32(6):448-57 [12059991.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6659-66 [12438264.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):548-54 [12555068.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):894-905 [12584569.001]
  • [Cites] Oncogene. 2003 Mar 20;22(11):1638-52 [12642867.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1270-9 [12649187.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5399-407 [12934099.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50402-11 [14523021.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1569-73 [15162527.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6109-18 [15342394.001]
  • [Cites] Science. 1995 Jul 7;269(5220):81-3 [7541555.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • (PMID = 18320073.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cysteine Proteinase Inhibitors; 0 / Leupeptins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / Tyrphostins; 0 / Vascular Endothelial Growth Factor A; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.10.2 / PTK2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2259457
  •  go-up   go-down


93. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S: Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer; 2008 Jan 29;8:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
  • METHODS: By immunohistochemistry, we assessed COX-2 expression in 24 hyperplastic polyps, 7 sessile serrated polyp/adenomas (SSA), 5 mixed polyps with SSA and adenoma, 27 traditional serrated adenomas, 515 non-serrated adenomas (tubular adenoma, tubulovillous adenoma and villous adenoma), 33 adenomas with intramucosal carcinomas, 96 adenocarcinomas with serration (corkscrew gland) and 111 adenocarcinomas without serration.
  • RESULTS: Strong (2+) COX-2 overexpression was more common in non-serrated adenomas (28% = 143/515) than in hyperplastic polyps (4.2% = 1/24, p = 0.008) and serrated polyps (7 SSAs and 5 mixed polyps) (0% = 0/12, p = 0.04).
  • Furthermore, any (1+/2+) COX-2 overexpression was more frequent in non-serrated adenomas (60% = 307/515) than in hyperplastic polyps (13% = 3/24, p < 0.0001) and serrated polyps (SSAs and mixed polyps) (25% = 3/12, p = 0.03).
  • Traditional serrated adenomas and non-serrated adenomas showed similar frequencies of COX-2 overexpression.
  • Regardless of serration, COX-2 overexpression was frequent (approximately 85%) in colorectal adenocarcinomas.
  • Tumor location was not significantly correlated with COX-2 overexpression, although there was a trend towards higher frequencies of COX-2 overexpression in distal tumors (than proximal tumors) among hyperplastic polyps, SSAs, mixed polyps, traditional serrated adenomas and adenocarcinomas.
  • CONCLUSION: COX-2 overexpression is infrequent in hyperplastic polyp, SSA and mixed polyp with SSA and adenoma, compared to non-serrated and serrated adenoma.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1998 Jul;28(7):421-6 [9739782.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4044-8 [10945606.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):350-8 [10419916.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8465-71 [15623626.001]
  • [Cites] Dig Dis Sci. 2004 Nov-Dec;49(11-12):1906-11 [15628724.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):130-8 [15654792.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):429-36 [15767794.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6738-44 [16166455.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Oncology. 2005;69 Suppl 1:33-7 [16210875.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] BMC Cancer. 2006;6:9 [16409625.001]
  • [Cites] Histopathology. 2006 Mar;48(4):431-7 [16487365.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):458-64 [16820091.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] BMC Cancer. 2006;6:181 [16831226.001]
  • [Cites] J Pathol. 2006 Oct;210(2):137-40 [16917802.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1319-23 [11584208.001]
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):144-9 [12049307.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):705-8 [12598303.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):786-92 [12794581.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Aug;129(8):449-55 [12884030.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):267-71 [14734479.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):213-9 [14745394.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jun;16(6):619-25 [15167166.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Ann Intern Med. 1994 Aug 15;121(4):241-6 [8037405.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] Crit Rev Oncog. 2006 Jul;12(1-2):27-39 [17078205.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2195-8 [17522404.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5473-7 [9850081.001]
  • (PMID = 18230181.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P50 CA127003
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC2257954
  •  go-up   go-down


94. Kondo E, Miyake T, Shibata M, Kimura T, Iwagaki H, Nakamura S, Tanaka T, Ohara N, Ichimura K, Oka T, Yanai H, Shibasaki F, Yoshino T: Expression of phosphorylated Ser70 of Bcl-2 correlates with malignancy in human colorectal neoplasms. Clin Cancer Res; 2005 Oct 15;11(20):7255-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To elucidate this question that may suggest the biological role, we molecularly screened a panel of human colorectal adenomas and adenocarcinomas for endogenous expression of pSer70 Bcl-2.
  • EXPERIMENTAL DESIGN: An antibody specific against pSer70 Bcl-2 was generated for thorough immunohistochemical examination of paraffin-embedded tumor specimens, allowing detection of the endogenously expressed antigen among a range of Bcl-2-positive colorectal neoplasms, including 75 tubular adenomas, 114 adenocarcinomas, and 15 cases of cancer in adenomas.
  • RESULTS: Loss of pSer70 Bcl-2 expression was observed in adenocarcinomas in a differentiation-dependent manner (positivities: well differentiated 63%, moderately differentiated 52%, and poorly differentiated 12%), whereas tubular adenomas maintained their expression (positivity 88%).
  • Interestingly, an inverse correlation was found between expression of pSer70 Bcl-2 and Ki-67 antigen in those cases of cancer in adenoma (P < 0.01).
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243795.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 452VLY9402 / Serine
  •  go-up   go-down


95. Shi Z, Dragin N, Miller ML, Stringer KF, Johansson E, Chen J, Uno S, Gonzalez FJ, Rubio CA, Nebert DW: Oral benzo[a]pyrene-induced cancer: two distinct types in different target organs depend on the mouse Cyp1 genotype. Int J Cancer; 2010 Nov 15;127(10):2334-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyp1a1(-/-) mice revealed markedly increased CYP1B1 mRNA levels in the PSI, and between 8 and 12 weeks developed unique PSI adenomas and adenocarcinomas.
  • PSI adenocarcinomas exhibited striking upregulation of the Xist gene, suggesting epigenetic silencing of specific genes on the Y-chromosome; the Rab30 oncogene was upregulated; the Nr0b2 tumor suppressor gene was downregulated; paradoxical overexpression of numerous immunoglobulin kappa- and heavy-chain variable genes was found-although the adenocarcinoma showed no immunohistochemical evidence of being lymphatic in origin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D258-61 [14681407.001]
  • [Cites] Br Med Bull. 2003;68:167-82 [14757716.001]
  • [Cites] Mol Pharmacol. 2004 May;65(5):1225-37 [15102951.001]
  • [Cites] Biotechniques. 2004 May;36(5):790-6 [15152598.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23847-50 [15028720.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(9):970-8 [15198916.001]
  • [Cites] Mol Pharmacol. 1975 Nov;11(6):850-65 [54870.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):2777-83 [679184.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5358-61 [281685.001]
  • [Cites] Biochem Pharmacol. 1979;28(1):149-51 [758905.001]
  • [Cites] J Natl Cancer Inst. 1981 May;66(5):913-7 [6262559.001]
  • [Cites] Drug Metab Rev. 1982;13(2):235-47 [6807663.001]
  • [Cites] Pharmacol Rev. 1982 Jun;34(2):189-222 [6287505.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):4875-917 [6814745.001]
  • [Cites] Carcinogenesis. 1983;4(5):513-7 [6850980.001]
  • [Cites] Environ Health Perspect. 1988 Apr;77:11-21 [3289903.001]
  • [Cites] Crit Rev Toxicol. 1989;20(3):153-74 [2558673.001]
  • [Cites] Am J Med. 1992 Jul 15;93(1A):13S-17S [1496998.001]
  • [Cites] Drug Metab Rev. 1994;26(1-2):125-63 [8082562.001]
  • [Cites] Nat Genet. 1996 Oct;14(2):128-9 [8841177.001]
  • [Cites] Carcinogenesis. 1998 Jan;19(1):117-24 [9472702.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1977-82 [10051580.001]
  • [Cites] Epigenetics. 2008 Sep;3(5):246-9 [19013827.001]
  • [Cites] J Cell Biol. 2008 Nov 17;183(4):607-15 [19001129.001]
  • [Cites] Mucosal Immunol. 2008 Nov;1(6):460-9 [19079213.001]
  • [Cites] J Biol Chem. 2008 Dec 26;283(52):36061-5 [18713746.001]
  • [Cites] Hum Genomics. 2008 Sep;3(1):87-97 [19129093.001]
  • [Cites] Bioinformatics. 2009 Jan 15;25(2):211-7 [19038984.001]
  • [Cites] Prog Histochem Cytochem. 2007;42(2):61-110 [17616258.001]
  • [Cites] Surg Today. 2007;37(9):725-34 [17713724.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] APMIS. 2007 Oct;115(10):1147-60 [18042148.001]
  • [Cites] Free Radic Biol Med. 2008 Feb 15;44(4):570-83 [17997381.001]
  • [Cites] J Allergy Clin Immunol. 2008 Feb;121(2 Suppl):S380-3; quiz S415 [18241686.001]
  • [Cites] Trends Endocrinol Metab. 2008 Mar;19(2):74-81 [18054496.001]
  • [Cites] Cancer Sci. 2008 May;99(5):849-55 [18380788.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Biol Chem. 2008 Apr;389(4):323-31 [18225988.001]
  • [Cites] Tissue Antigens. 2008 Jul;72(1):1-10 [18498291.001]
  • [Cites] Hepatology. 2008 Jul;48(1):289-98 [18537191.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] J Exp Med. 2008 Aug 4;205(8):1755-61 [18663129.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 17;100(18):1310-7 [18780863.001]
  • [Cites] Cell Mol Immunol. 2008 Oct;5(5):319-24 [18954554.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2932-8 [16374581.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1103-14 [16377763.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4792-801 [14581350.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):225-32 [19153668.001]
  • [Cites] Cell Death Differ. 2008 Jul;15(7):1103-12 [18552861.001]
  • [Cites] Biochem Pharmacol. 2000 Jan 1;59(1):65-85 [10605936.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):184-9 [10623596.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1129-42 [11007951.001]
  • [Cites] Ann N Y Acad Sci. 2000;919:148-70 [11083106.001]
  • [Cites] Drug Metab Rev. 2001 Feb;33(1):1-35 [11270659.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):1903-30 [11751421.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2733-40 [12529989.001]
  • [Cites] Bioinformatics. 2003 Feb 12;19(3):368-75 [12584122.001]
  • [Cites] Ind Health. 2003 Jul;41(3):127-38 [12916742.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):199-204 [10102353.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(24):2916-20 [16374579.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1625-32 [16863570.001]
  • [Cites] Exp Anim. 2006 Jul;55(4):343-7 [16880681.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):940-6 [17183066.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):661-3 [16837629.001]
  • (PMID = 20127859.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006096-149007; United States / NIEHS NIH HHS / ES / P30 ES006096-139007; United States / NIEHS NIH HHS / ES / ES006096-119007; United States / NIEHS NIH HHS / ES / ES014403-03; United States / NIEHS NIH HHS / ES / R01 ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-159007; United States / NIEHS NIH HHS / ES / ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-149007; United States / NIEHS NIH HHS / ES / R01 ES014403; United States / NIEHS NIH HHS / ES / R01 ES014403-04; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / R01 ES014403-03S1; United States / NIEHS NIH HHS / ES / ES014403-03S1; United States / NIEHS NIH HHS / ES / P30 ES006096-159007; United States / NIEHS NIH HHS / ES / ES006096-139007; United States / NIEHS NIH HHS / ES / ES006096-129007; United States / NIEHS NIH HHS / ES / R01 ES014403-03; United States / NIEHS NIH HHS / ES / P30 ES006096-119007; United States / NIEHS NIH HHS / ES / P30 ES006096-129007; United States / NIEHS NIH HHS / ES / P30 ES06096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp1b1 protein, mouse; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
  • [Other-IDs] NLM/ NIHMS184552; NLM/ PMC2917638
  •  go-up   go-down


96. Bin Park S, Lee JH, Lee YH, Song MJ, Choi HJ: Multilocular cystic lesions in the uterine cervix: broad spectrum of imaging features and pathologic correlation. AJR Am J Roentgenol; 2010 Aug;195(2):517-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this article is to describe the broad spectrum and imaging features of multilocular cystic lesions in the uterine cervix from benign lesions, such as uterine cervicitis, endocervical hyperplasia, nabothian cyst, and tunnel cluster, to malignant lesions including adenocarcinoma and adenoma malignum.

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651212.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


98. Klosterman E, Colitz CM, Chandler HL, Kusewitt DF, Saville WJ, Dubielzig RR: Immunohistochemical properties of ocular adenomas, adenocarcinomas and medulloepitheliomas. Vet Ophthalmol; 2006 Nov-Dec;9(6):387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical properties of ocular adenomas, adenocarcinomas and medulloepitheliomas.
  • Ocular medulloepitheliomas, adenomas and adenocarcinomas share a common phenotype and originate from the optic cup neuroectoderm.
  • CK20 immunostaining was found in the adenomas but not in the adenocarcinomas or medulloepitheliomas.
  • AE1/AE3 expression was present more consistently in the adenocarcinomas and less frequently in the adenomas.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Adenocarcinoma / veterinary. Adenoma / diagnosis. Adenoma / immunology. Adenoma / veterinary. Animals. Dogs. Female. Immunohistochemistry / veterinary. Male. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / immunology. Neuroectodermal Tumors, Primitive / veterinary. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076871.001).
  • [ISSN] 1463-5216
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Grady WM, Ulrich CM: DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas? Gut; 2007 Mar;56(3):318-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas?

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Gut. 2007 Mar;56(3):380-4 [16891355.001]
  • [Cites] Mutat Res. 2000 May 30;450(1-2):139-53 [10838139.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):835-42 [10963127.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27851-7 [10878012.001]
  • [Cites] Mutat Res. 2001 Aug 22;495(1-2):103-15 [11448648.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):168-70 [12107837.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] Oncology. 2002;63(4):393-7 [12417795.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3518S-3521S [12421880.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):625-35 [12727789.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):320-3 [14973087.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):281-6 [15140540.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1089-93 [15452166.001]
  • [Cites] Biochemistry. 1996 Jan 30;35(4):1328-34 [8573590.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702 [9671741.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1473-80 [15831531.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):781-9 [16708352.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [CommentOn] Gut. 2007 Mar;56(3):380-4 [16891355.001]
  • (PMID = 17339242.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059045; United States / NCI NIH HHS / CA / R01 CA114467; United States / NCI NIH HHS / CA / R01 CA59045
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 29
  • [Other-IDs] NLM/ PMC1856827
  •  go-up   go-down


100. Kim HO, Hwang SI, Yoo CH, Kim H: Preoperative colonoscopy for patients with gastric adenocarcinoma. J Gastroenterol Hepatol; 2009 Nov;24(11):1740-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative colonoscopy for patients with gastric adenocarcinoma.
  • BACKGROUND AND AIM: In patients with gastric adenocarcinoma (GA), the most common double primary cancer is colorectal cancer.
  • The prevalence of colorectal neoplasms (CRN, adenoma and adenocarcinoma) was evaluated according to age, sex, body mass index (BMI) and stage, location and differentiation of GA.
  • Synchronous adenoma and adenocarcinoma were detected in 68 (33.2%) and four (2.0%) patients, respectively.
  • All of the GA patients with synchronous colorectal adenocarcinoma were older than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonoscopy. Colorectal Neoplasms / pathology. Gastrectomy. Mass Screening / methods. Neoplasms, Second Primary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Databases as Topic. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Preoperative Care. Prevalence. Risk Assessment. Risk Factors






Advertisement